Sphingosine-1-phosphate receptor 2, 3, and 4 (S1PR2/S1PR3/S1PR4)

The sphingosine-1-phosphate receptor 2 (S1P2), receptor 3 (S1P3), and receptor 4 (S1P4) are subtypes of the G protein-coupled receptor family that respond to the bioactive lipid sphingosine-1-phosphate (S1P). These receptors are critical mediators of diverse biological processes, including cell migration, vascular stability, and immune cell trafficking. S1P2 and S1P3 are widely expressed and are particularly involved in regulating vascular tone and promoting fibrotic responses in organs like the heart and lungs. S1P4 is more restricted to lymphoid and hematopoietic tissues, where it influences the differentiation and function of immune cells such as T cells and dendritic cells. In disease, these receptors are implicated in conditions ranging from autoimmune disorders and chronic inflammation to cancer and cardiovascular disease. While several S1P receptor modulators are approved for treating multiple sclerosis and ulcerative colitis, most target S1P1, S1P4, and S1P5; S1P3 is often avoided in newer drugs due to its association with bradycardia, and S1P2 remains a target of interest for its roles in vascular and fibrotic pathologies. Fingolimod, the first approved S1P modulator, acts as an agonist on S1P3 and S1P4, while newer agents like etrasimod maintain activity on S1P4 but avoid S1P3 to improve safety.

Other names

S1PR2S1PR3S1PR4EDG5EDG3EDG6Endothelial differentiation G-protein-coupled receptor 5Endothelial differentiation G-protein-coupled receptor 3Endothelial differentiation G-protein-coupled receptor 6H218LPB2LPB3LPC1

Agonism leading to functional antagonism via receptor internalization and degradation, or direct antagonism of the G protein-coupled receptors.